公开(公告)号：US20080193464A1

公开(公告)日：2008-08-14

申请号：US11570480

申请日：2005-06-30

Applicant: Anne Philippi ,  Francis Rousseau ,  Peter Brooks ,  Jorg Hager

Inventor： Anne Philippi ,  Francis Rousseau ,  Peter Brooks ,  Jorg Hager

IPC: A61K39/395 ,  C12Q1/68 ,  A61K31/70 ,  A61K33/00 ,  A61P25/00 ,  A61K31/135 ,  A61K31/38 ,  G01N33/567

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  Y10T436/143333

Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB1 gene of chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCB1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperse syndrome, pervasive developmental disorder, childhood disintegrate disorder, mental retardation, anxiety, depression, attention deficit hyperactive disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological disease.

Abstract translation: 本发明公开了一种人类自闭症易感性基因的鉴定，其可用于诊断，预防和治疗自闭症及相关疾病，以及用于筛选治疗活性药物。 本发明更具体地公开了16号染色体的PRKCB1基因及其某些等位基因与自闭症易感性有关，代表治疗干预的新靶点。 本发明涉及PRKCB1基因和表达产物中的特定突变，以及基于这些突变的诊断工具和试剂盒。 本发明可用于诊断Asperse综合征，普遍发育障碍，儿童分解障碍，精神发育迟滞，焦虑，抑郁，注意力缺陷多动障碍，语言延迟或语言障碍，癫痫的倾向，检测，预防和/或治疗 ，代谢紊乱，免疫障碍，双相性精神障碍和其他精神疾病和神经疾病。

公开(公告)号：US07205662B2

公开(公告)日：2007-04-17

申请号：US10789953

申请日：2004-02-26

Applicant: Mukundan Narasimhan ,  Peter Brooks ,  Richard E. Demaray

Inventor： Mukundan Narasimhan ,  Peter Brooks ,  Richard E. Demaray

IPC: H01L21/48

CPC classification number: C23C14/345 ,  C23C14/35 ,  H01L21/02145 ,  H01L21/02164 ,  H01L21/02178 ,  H01L21/02186 ,  H01L21/02192 ,  H01L21/02194 ,  H01L21/022 ,  H01L21/02266 ,  H01L21/02304 ,  H01L21/31604 ,  H01L21/31608 ,  H01L21/31612 ,  H01L21/31616 ,  H01L21/31637 ,  H01L21/31691 ,  H01L51/5253 ,  H01L51/5256 ,  H01L51/5265 ,  Y10S438/958

Abstract: In accordance with the present invention, a dielectric barrier layer is presented. A barrier layer according to the present invention includes a densified amorphous dielectric layer deposited on a substrate by pulsed-DC, substrate biased physical vapor deposition, wherein the densified amorphous dielectric layer is a barrier layer. A method of forming a barrier layer according to the present inventions includes providing a substrate and depositing a highly densified, amorphous, dielectric material over the substrate in a pulsed-dc, biased, wide target physical vapor deposition process. Further, the process can include performing a soft-metal breath treatment on the substrate. Such barrier layers can be utilized as electrical layers, optical layers, immunological layers, or tribological layers.

公开(公告)号：US20070077199A1

公开(公告)日：2007-04-05

申请号：US11486894

申请日：2006-07-14

Applicant: Jeffry Watkins ,  William Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

Inventor： Jeffry Watkins ,  William Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

IPC: A61K51/00 ,  G01N33/574 ,  A61K39/395 ,  C07K16/30 ,  C07K16/46

CPC classification number: C07K16/30 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565

Abstract: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Abstract translation: 本发明提供抗体或其功能片段，其接枝抗体或其功能片段，其包含一个或多个在重链CDR的一个或多个CDR中具有至少一个氨基酸取代的互补决定区（CDR），其中 抗体或其功能片段对隐窝胶原表位具有特异性结合活性。 本发明还提供了使用具有对神经胶原表位具有特异性结合活性的抗体的方法，包括抑制血管发生，肿瘤生长和转移的方法。

公开(公告)号：US20060289653A1

公开(公告)日：2006-12-28

申请号：US11165738

申请日：2005-06-24

Applicant: Carl Wittenberg ,  Peter Brooks

Inventor： Carl Wittenberg ,  Peter Brooks

IPC: G06K7/10 ,  G02B26/08

CPC classification number: G02B7/1821 ,  G02B26/105

Abstract: A taut, torsional flexure is used in a compact drive for scanning light and is of beneficial use in a lightweight, compact image projection module, especially for mounting in a housing having a light-transmissive window, the module being operative for causing selected pixels in a raster pattern to be illuminated to produce an image of high resolution of VGA quality in color.

Abstract translation: 在紧凑型驱动器中使用绷紧的扭转挠曲用于扫描光，并且在轻量级紧凑的图像投影模块中是有益的，特别是用于安装在具有透光窗口的壳体中，该模块可操作用于使所选择的像素 要被照亮的光栅图案以产生VGA质量的高分辨率的图像。

公开(公告)号：US20060088540A1

公开(公告)日：2006-04-27

申请号：US11227524

申请日：2005-09-15

Applicant: Peter Brooks ,  Jingsong Xu ,  Eric Petitclerc

Inventor： Peter Brooks ,  Jingsong Xu ,  Eric Petitclerc

IPC: A61K39/395 ,  C07K16/30

CPC classification number: A61K39/3955 ,  A61K31/00 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for theraputic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.

Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性胶原但不与胶原天然三重螺旋形式结合的拮抗剂来抑制组织中血管生成的方法。 本发明的拮抗剂可以靶向例如I型，II型，III型，IV型，V型及其组合的变性胶原。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及使用这种拮抗剂作为血管生成诊断标志物的方法是体内和体外的正常或患病组织。 拮抗剂包括被称为HUI77，HUIV26和XL313的单克隆抗体。

公开(公告)号：US5753230A

公开(公告)日：1998-05-19

申请号：US210715

申请日：1994-03-18

Applicant: Peter Brooks ,  David A. Cheresh

Inventor： Peter Brooks ,  David A. Cheresh

IPC: A61K39/00 ,  C12N15/02 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/78 ,  C07K16/28 ,  C07K16/30 ,  C12P21/08 ,  A61K49/00 ,  C07K16/18

CPC classification number: C07K14/78 ,  C07K14/70557 ,  C07K16/2848 ,  C07K16/30 ,  A61K2039/505 ,  A61K38/00

Abstract: The present invention describes methods for inhibition of angiogenesis in tissues using vitronectin .alpha..sub.v .beta..sub.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing anti-.alpha..sub.v .beta..sub.3 monoclonal antibodies.

Abstract translation: 本发明描述了使用玻连蛋白αvβ3拮抗剂抑制组织中血管生成的方法，特别是使用含有抗αvβ3单克隆抗体的治疗组合物抑制发炎组织和肿瘤组织和转移中的血管生成。

公开(公告)号：US20140037571A1

公开(公告)日：2014-02-06

申请号：US14002014

申请日：2012-03-22

Applicant: Matthew Peter Brooks

Inventor： Matthew Peter Brooks

IPC: A61L9/014

CPC classification number: A61K8/416 ,  A61K8/362 ,  A61K8/37 ,  A61L9/01 ,  A61L9/014 ,  A61L2209/21 ,  A61L2209/22 ,  A61Q13/00 ,  A61Q15/00 ,  C11B9/0019

Abstract: A malodour-counteracting composition containing(i) a salt of general formula (I) R1R2R3R4N+X−  (I) wherein R1, R2, R3, R4 are independently selected from C1-4 alkyl, or R1, R2, R3, R4 may together constitute a nitrogen-containing cyclic system in which the nitrogen is part of a pyridinium or an imidazolinium ring; and X− is a counterion characterised by its protonated form having an acidity constant (pKa) lying between 1 and 6; and (ii) an alpha, beta-unsaturated carbonyl compound of the general formula R5R6C═CR7C(═O)YR8  (II) wherein R5, R6, R7 and R8 are independently selected from hydrogen and C1-10 hydrocarbyl residues which may be saturated, unsaturated, aromatic, cyclic, branched or unbranched, and are optionally substituted, or R5, R6, R7 and R8 may together constitute a cyclic system and Y is oxygen or a single covalent bond, with the proviso that Y is a covalent bond when R8 is hydrogen. The composition may be incorporated into consumer products and is able to remove malodours from the air or from surfaces.

Abstract translation: 包含（i）通式（I）的盐的恶臭反作用组合物其中R 1，R 2，R 3，R 4独立地选自C 1-4烷基或R 1，R 2，R 3，R 4可以 一起构成含氮环系，其中氮是吡啶鎓或咪唑啉环的一部分; 而X-是抗衡离子，其特征在于其质子化形式具有介于1和6之间的酸度常数（pKa）; 和（ii）通式为R 5 R 6 C = CR 7 C（= O）Y R 8（II）的α，β-不饱和羰基化合物，其中R 5，R 6，R 7和R 8独立地选自氢和可以饱和的C 1-10烃基残基 ，不饱和的，芳族的，环状的，支链的或非支链的，并且是任选取代的，或者R 5，R 6，R 7和R 8可以一起构成环状体系，Y是氧或单个共价键，条件是当Y是共价键时， R8是氢。 组合物可以并入消费品中，并且能够从空气或表面除去恶臭。

公开(公告)号：US20130259844A1

公开(公告)日：2013-10-03

申请号：US13876386

申请日：2011-09-29

Applicant: Peter Brooks ,  Jane Beal ,  Soumela Savvidou ,  Vlasta Demeckova

Inventor： Peter Brooks ,  Jane Beal ,  Soumela Savvidou ,  Vlasta Demeckova

IPC: A23L1/30 ,  C12R1/225 ,  C12R1/25 ,  C12N1/20

CPC classification number: C12N1/20 ,  A23C9/1234 ,  A23L33/135 ,  A23L33/40 ,  A23V2002/00 ,  A23Y2220/67 ,  A23Y2220/79 ,  C12R1/225 ,  C12R1/25 ,  A23V2200/3204

Abstract: A fermented foodstuff composition for human consumption is provided, the foodstuff composition being prepared by the fermentation of a foodstuff substrate with a lactic acid producing bacteria, the lactic acid bacteria being characterised by: a) being viable under the conditions prevailing in the human gastrointestinal tract; b) being a bacteria capable of aggregating and/or coaggregating with one or more pathogens; and c) being able to produce upon fermentation in the foodstuff substrate lactic acid in an amount of at least a minimum inhibitory concentration of lactic acid.

Abstract translation: 提供了一种用于人类消费的发酵食品组合物，该食品组合物通过用乳酸生产细菌发酵食品基质来制备，该乳酸菌的特征在于：a）在人类胃肠道中普遍存在的条件下是可行的 ; b）是能够聚集和/或聚集一种或多种病原体的细菌; 和c）能够在至少最低限度的乳酸抑制浓度的量的食品底物乳酸发酵中产生。

公开(公告)号：US20110251978A1

公开(公告)日：2011-10-13

申请号：US13094492

申请日：2011-04-26

Applicant: Gregory Bryn Davies ,  Daniel Pollard Egan ,  Peter Brooks ,  Mitchell Cox

Inventor： Gregory Bryn Davies ,  Daniel Pollard Egan ,  Peter Brooks ,  Mitchell Cox

IPC: G06Q40/00

CPC classification number: G06Q40/00 ,  G06Q40/06

Abstract: One or more aspects comprise a computer system comprising one or more servers that: (a) provide a financial personality assessment questionnaire to a user; and (b) receive data describing said user's responses to one or more questions in said questionnaire; and one or more processors in communication with said one or more servers that: (a) based on said data describing said user's responses, assess said user's investment-related attitudes across a plurality of scales and produce a multi-dimensional financial personality identifier for said user; and (b) construct a user risk profile for said user derived from said multi-dimensional financial personality identifier.

Abstract translation: 一个或多个方面包括包括一个或多个服务器的计算机系统，所述服务器：（a）向用户提供财务人格评估问卷; 和（b）接收描述所述用户对所述问卷中的一个或多个问题的回答的数据; 以及与所述一个或多个服务器通信的一个或多个处理器，所述处理器与所述一个或多个服务器通信：（a）基于描述所述用户的响应的所述数据，评估所述用户在多个比例尺上的投资相关态度，并产生用于所述 用户; 和（b）从所述多维财务人格标识符构建用于所述用户的用户风险简档。

公开(公告)号：US07763247B2

公开(公告)日：2010-07-27

申请号：US12070146

申请日：2008-02-15

Applicant: Jeffry D. Watkins ,  William D. Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

Inventor： Jeffry D. Watkins ,  William D. Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

IPC: A61K39/00

CPC classification number: C07K16/30 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565

Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Abstract translation: 本发明提供了接枝抗体或其功能片段，其包含一个或多个在重链CDR的一个或多个CDR中具有至少一个氨基酸取代的互补决定区（CDR），其中所述接枝抗体或其功能片段具有特异性 隐形胶原表位的结合活性。 本发明还提供了使用具有对神经胶原表位具有特异性结合活性的抗体的方法，包括抑制血管生成，肿瘤生长和转移的方法。